“The unique fusion of individual innovative technologies will provide a novel diagnostic tool leading to a better understanding of the underlying pathophysiology of rare anaemia.”

Lars Kaestner, Coordinator of CoMMiTMenT


The consortium has been designed to provide a dynamic synergy between the SMEs and the academic and clinical partners. Additional value is provided through well-established connections of consortium members to the anaemia medical research and clinical diagnostics communities as well as to hospitals and patients. The integration of the commercial SMEs with the academic research organisations will provide a culture of innovation within the consortium that will continue beyond the duration of the project.

The impact considerations of CoMMiTMenT can be divided into three subsections:

  1. Medical impact on the diagnosis, treatment, and personalised medication of RA
  2. Scientific/technological impact on the development of combined microscopy methodology (µCOSMOS)
  3. Economic Impact